A once-daily triple-drug HIV regimen containing an experimental integrase inhibitor performed better in suppressing the virus than Atripla in a Phase III trial, developers of the new drug say. The trial pitted dolutegravir in combination with two older HIV drugs against the three-drug Atripla.
Results from the SINGLE trial found 88 percent of patients taking the dolutegravir-based regimen achieved undetectable virus at 48 weeks, compared with 81 percent for Atripla patients. Dolutegravir is being developed by Japanese partner Shionogi & Co. and ViiV Healthcare, a partnership of UK-based GlaxoSmithKline and US-based Pfizer.
Complete trial results will be presented at an upcoming scientific meeting. In April, the first set of study results showed dolutegravir was as effective as twice-daily Isentress. Four Phase III studies due for reporting this year are designed to accompany regulatory filings in support of the drug.
Dolutegravir’s low-milligram dosing could make it easier to include in a fixed-dose combination pill, and there could be fewer side effects because a booster is not required.
Date of Publication
Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.